On the basis of these observations and the underlying genetics of the disease, PARP inhibition is gaining considerable attention as a novel systemic treatment for SCLC (i.e., NCT02289690, NCT02734004, NCT01286987). Here, PARP1 is linked to small cell lung carcinoma.